Skip to main content
UniHealth

Doctor search

Saurabh Dahiya, MD

Medical Oncology · Stanford

NPI 1184943730

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
17
3 carriers
Office
1

Offices

1 location · Stanford Health Care · 3,152 clinicians in this group

Looking this up.

Hospitals listed: Stanford Health Care · University of Maryland Medical Center. That is not proof they admit you there this week.

Plans that list them

17 plans · 3 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Dahiya’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

17 of 17 plans

Plans whose provider directory lists this clinician
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
DualConnect (HMO D-SNP)Santa Clara Family Health PlanListedSep 1, 2026

California Medical Board record

Licence A140273 · Current

Licensed to practise in California · since 2016 · expires 2027-06-30 · University of Delhi, Maulana Azad Medical College.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
  • University of Maryland Medical CenterBaltimore, MDAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of University of Maryland Medical System, which runs 13 hospitalsHome of Marlene and Stewart Greenebaum Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 70% would definitely recommend it
    Overall rating: 3 of 5 starsWorse than the national rate — Postoperative respiratory failure rate: 13.31 (11.23 to 15.39) · 3,373 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.333, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for University of Maryland Medical Center

Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 9 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at University of Maryland Medical Center
Postoperative respiratory failure rateComplications and deaths13.31 (11.23 to 15.39) · 3,373 casesWorseJul 2022 – Jun 2024
Clostridium Difficile (C.Diff)Infections0.333BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.76 (0.02 to 1.51) · 2,831 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.03 (0.87 to 1.19)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths180.76 (155.53 to 206) · 504 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.5 · 247 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7 · 93 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths14.8 · 78 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths12.8 · 222 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths11.8 · 106 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths10.2 · 452 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.6 · 2,934 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.23 (0.06 to 0.41) · 10,607 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.21 (0.05 to 0.38) · 11,275 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.38 (2.1 to 4.66) · 5,119 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.5 (0.6 to 2.4) · 3,028 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.72 (0.74 to 2.7) · 4,283 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.87 (4.22 to 7.52) · 3,266 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths2.08 (0.83 to 3.32) · 1,178 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.43 (0.04 to 0.82) · 9,810 casesNo differentJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.913No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections1.025No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.594No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections1.541No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.374No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.4 · 192 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits19.8 · 312 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits8.7 · 196 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-25.8 · 265 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-19.7 · 112 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.1 · 141 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits4.4 (3.5 to 5.6) · 974 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits10.5 (8.9 to 12.4) · 974 casesNo differentJan 2024 – Dec 2024
Rate of readmission for CABGUnplanned return visits9.2 · 111 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits18.1 · 147 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits14.3 (10.7 to 19.2) · 293 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.1 (0.8 to 1.5) · 228 casesNo differentJan 2024 – Dec 2024

What patients said (1,490 patients answered, 17% of those asked)

Patient survey stars by topic at University of Maryland Medical Center
Cleanliness2
Nurse communication3
Doctor communication3
Communication about medicines2
Discharge information4
Overall hospital rating3
Quietness2
Recommend hospital4
Share of patients giving the best answer at University of Maryland Medical Center
Room was "always" clean62%
Nurses "always" communicated well75%
Doctors "always" communicated well78%
Staff "always" explained56%
Yes, staff "did" give patients this information87%
Yes, staff "did" give patients information about help after discharge86%
Doctors "always" explained things so they could understand72%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect85%
Patients who gave a rating of "9" or "10" (high)68%
Staff "always" explained new medications71%
Nurses "always" explained things so they could understand71%
Nurses "always" listened carefully72%
Nurses "always" treated them with courtesy and respect81%
"Always" quiet at night51%
"YES", patients would definitely recommend the hospital70%
Staff "always" explained possible side effects42%
Yes, staff "did" give patients information about possible symptoms88%

Original Medicare doctor bills

$48,844

Medicare paid this office $48,844 for 98 people. Most of that is long return visits and Botox.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)80$29,900$127
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes19$11,233$104
Long return visit (40+ min)15$4,421$152
New patient visit (60+ min)14$2,278$163

Who their Medicare patients are

98 Original Medicare patients in 2024. Average age 71 · Women 54% · Also on Medicaid 21% · Health risk score 2.63. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.

Conditions among them: High blood pressure 66% · Atrial fibrillation 31% · Chronic kidney disease 29% · Coronary heart disease 26% · Depression 24% · Diabetes 23% · Dementia 18% · COPD 13% · Heart failure 12% · Cancer 12%.

The office billed $124,971, Medicare allowed $62,884 and paid $48,844; for 396 services of 6 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
202498396712.63$124,971$48,844
202357309712.93$114,821$36,332
202269341662.79$110,171$34,937
202170438652.51$115,917$44,389
202059275683.23$64,309$22,905
201951340702.81$86,684$29,010
201852299662.88$69,336$24,665
20171345671.54$7,937$3,730

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 2 services

Original Medicare services billed in 2023
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes32$17,004$110
Long return visit (40+ min)24$16,422$128

2022: 2 services

Original Medicare services billed in 2022
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes30$19,706$90
Long return visit (40+ min)38$9,884$127

2021: 4 services

Original Medicare services billed in 2021
Long return visit (40+ min)41$22,810$118
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes30$16,881$88
Return visit (30+ min)13$1,893$86
Hospital discharge day management, 30 minutes or less11$744$62

2020: 5 services

Original Medicare services billed in 2020
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes30$9,919$90
Long return visit (40+ min)20$5,646$90
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes19$2,485$62
Initial hospital care with moderate level of medical decision making at least 75 minutes11$2,021$168
Hospital discharge day management, 30 minutes or less18$1,140$63

2019: 4 services

Original Medicare services billed in 2019
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes29$12,466$86
Long return visit (40+ min)24$10,342$89
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes12$1,795$62
Hospital discharge day management, 30 minutes or less11$686$62

2018: 3 services

Original Medicare services billed in 2018
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes32$11,600$83
Long return visit (40+ min)14$9,266$92
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes11$1,103$61

Medicaid work

$5,311 in 2024

Medicaid paid $5,311 for 46 billed services this clinician did in 2024, up to 17 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)46$5,311
Medicaid work by year
202446117$5,311

Drugs they prescribed that Part D paid

$61,800

Pharmacies billed $61,800 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

167 generic and 16 brand-name prescriptions · $61,800 in drug cost · 56 antibiotic prescriptions to 22 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Posaconazole12$16,783$1,399
Sulfamethoxazole-Trimethoprim49$379$8
Acyclovir25$358$14
Ondansetron17$70$4
Allopurinol17$56$3

Year by year

Part D prescribing by year
202418343None9%$61,800
20239720NoneNone$12,557
2022103180% (0)19%$339,701
202117217None8%$167,719
202017018None19%$262,315
201917911NoneNone$86,824
201817614None12%$79,103
201713None0% (0)None$6,168
20164715NoneNone$12,286
2015832519% (16)22%$63,209
20148425NoneNone$10,824
20134321NoneNone$3,729

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 3 drugs

Part D drugs prescribed in 2023
Sulfamethoxazole-Trimethoprim19$199$10
Ondansetron12$101$8
Allopurinol12$39$3

2022: 1 drug

Part D drugs prescribed in 2022
Valacyclovir25$2,152$86

2021: 2 drugs

Part D drugs prescribed in 2021
Valacyclovir57$3,722$65
Pantoprazole14$364$26

2020: 3 drugs

Part D drugs prescribed in 2020
Valacyclovir21$1,693$81
Sulfamethoxazole-Trimethoprim13$106$8
Pantoprazole13$84$6

2019: 4 drugs

Part D drugs prescribed in 2019
Atovaquone14$9,436$674
Valacyclovir30$2,945$98
Pantoprazole17$432$25
Sulfamethoxazole-Trimethoprim18$141$8

2018: 6 drugs

Part D drugs prescribed in 2018
Noxafil11$65,142$5,922
Valacyclovir25$1,409$56
Triamcinolone Acetonide19$364$19
Sulfamethoxazole-Trimethoprim21$110$5
Ranitidine14$79$6
Carvedilol11$39$4

2015: 2 drugs

Part D drugs prescribed in 2015
Anastrozole16$1,290$81
Oxycodone11$178$16

2014: 2 drugs

Part D drugs prescribed in 2014
Anastrozole23$1,794$78
Hydrocortisone11$125$11

Money from drug and device companies

$40,588 in 2025

Industry payments by year
2025726$38,340$40,588
2024631$22,260$33,267
2023519$9,744$11,694
202258$4,420$4,834
202112$1,845$1,900
202011$1,580$1,580
201924None$289

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Kite PharmaYescarta$17,142
15 payments
  • Meals for Yescarta · 2025-10-23 · $46
  • Meals for Yescarta · 2025-05-21 · $100
  • Consulting for Yescarta · 2025-05-04 · $15,210
  • Meals for Yescarta · 2025-05-04 · $38
  • Meals for Yescarta · 2025-05-04 · $53
  • Meals for Yescarta · 2025-05-04 · $67
  • Meals for Yescarta · 2025-05-03 · $17
  • Meals for Yescarta · 2025-05-03 · $28
  • Meals for Yescarta · 2025-05-03 · $58
  • Meals for Yescarta · 2025-05-03 · $127
  • Travel for Yescarta · 2025-05-02 · $427
  • Travel for Yescarta · 2025-05-02 · $757
  • Meals for Yescarta · 2025-04-09 · $2
  • Meals for Yescarta · 2025-03-25 · $35
  • Meals for Yescarta · 2025-02-19 · $178
Janssen Research & DevelopmentTecvayli$11,155
3 payments
  • Consulting for Tecvayli · 2025-12-10 · $3,395
  • Consulting for Tecvayli · 2025-10-03 · $4,365
  • Consulting for Tecvayli · 2025-04-04 · $3,395
E.R. Squibb & Sons L.L.C.Breyanzi$6,155
3 payments
  • Consulting · 2025-09-05 · $1,910
  • Consulting for Breyanzi · 2025-06-11 · $1,380
  • Consulting · 2025-03-27 · $2,865
Novartis PharmaceuticalsNone$4,200
1 payment
  • Consulting · 2025-06-10 · $4,200
Janssen Global ServicesNone$1,620
1 payment
  • Consulting · 2025-10-31 · $1,620
CelgeneBreyanzi$251
2 payments
  • Meals for Breyanzi · 2025-05-30 · $28
  • Meals for Breyanzi · 2025-05-28 · $223
See all 26 published payments
Every published payment
Janssen Research & DevelopmentConsulting · 2025-12-10Tecvayli$3,395
Janssen Global ServicesConsulting · 2025-10-31None$1,620
Kite PharmaMeals · 2025-10-23Yescarta$46
Janssen Research & DevelopmentConsulting · 2025-10-03Tecvayli$4,365
E.R. Squibb & Sons L.L.C.Consulting · 2025-09-05None$1,910
AstraZeneca Pharmaceuticals LPMeals · 2025-06-13None$65
E.R. Squibb & Sons L.L.C.Consulting · 2025-06-11Breyanzi$1,380
Novartis PharmaceuticalsConsulting · 2025-06-10None$4,200
CelgeneMeals · 2025-05-30Breyanzi$28
CelgeneMeals · 2025-05-28Breyanzi$223
Kite PharmaMeals · 2025-05-21Yescarta$100
Kite PharmaConsulting · 2025-05-04Yescarta$15,210
Kite PharmaMeals · 2025-05-04Yescarta$38
Kite PharmaMeals · 2025-05-04Yescarta$53
Kite PharmaMeals · 2025-05-04Yescarta$67
Kite PharmaMeals · 2025-05-03Yescarta$17
Kite PharmaMeals · 2025-05-03Yescarta$28
Kite PharmaMeals · 2025-05-03Yescarta$58
Kite PharmaMeals · 2025-05-03Yescarta$127
Kite PharmaTravel · 2025-05-02Yescarta$427
Kite PharmaTravel · 2025-05-02Yescarta$757
Kite PharmaMeals · 2025-04-09Yescarta$2
Janssen Research & DevelopmentConsulting · 2025-04-04Tecvayli$3,395
E.R. Squibb & Sons L.L.C.Consulting · 2025-03-27None$2,865
Kite PharmaMeals · 2025-03-25Yescarta$35
Kite PharmaMeals · 2025-02-19Yescarta$178
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $33,267

Payments by company in 2024
Gilead SciencesYescarta$12,428
5 payments
  • Consulting · 2024-12-20 · $3,050
  • Meals · 2024-12-06 · $60
  • Meals · 2024-12-06 · $37
  • Meals for Yescarta · 2024-04-24 · $112
  • Travel · 2024-04-21 · $9,169
Kite PharmaYescarta$11,879
20 payments
  • Meals · 2024-12-09 · $144
  • Meals · 2024-12-08 · $125
  • Travel for Yescarta · 2024-11-27 · $47
  • Meals for Yescarta · 2024-11-27 · $21
  • Meals for Yescarta · 2024-11-27 · $14
  • Meals for Yescarta · 2024-11-27 · $19
  • Travel for Yescarta · 2024-11-27 · $78
  • Travel for Yescarta · 2024-11-27 · $19
  • Consulting for Yescarta · 2024-11-14 · $10,450
  • Meals for Yescarta · 2024-11-09 · $25
  • Meals for Yescarta · 2024-11-09 · $50
  • Meals for Yescarta · 2024-11-09 · $50
  • Travel for Yescarta · 2024-11-09 · $181
  • Travel for Yescarta · 2024-11-08 · $408
  • Meals · 2024-10-03 · $17
  • Meals for Yescarta · 2024-08-26 · $24
  • Meals for Yescarta · 2024-08-26 · $4
  • Meals for Yescarta · 2024-06-11 · $69
  • Meals for Yescarta · 2024-05-01 · $9
  • Meals · 2024-02-22 · $125
Janssen Research & DevelopmentTecvayli$4,608
2 payments
  • Consulting for Tecvayli · 2024-10-23 · $1,940
  • Consulting for Tecvayli · 2024-10-02 · $2,668
E.R. Squibb & Sons L.L.C.None$4,152
2 payments
  • Consulting · 2024-12-30 · $3,460
  • Consulting · 2024-09-05 · $692
CelgeneNone$125
1 payment
  • Meals · 2024-04-03 · $125
Novartis PharmaceuticalsKymriah$75
1 payment
  • Meals for Kymriah · 2024-04-19 · $75

2023: $11,694

Payments by company in 2023
Kite PharmaYescarta$5,992
12 payments
  • Meals for Yescarta · 2023-12-20 · $3
  • Meals · 2023-12-09 · $117
  • Meals for Yescarta · 2023-12-04 · $22
  • Meals for Yescarta · 2023-10-26 · $5
  • Meals for Yescarta · 2023-09-27 · $10
  • Meals for Yescarta · 2023-09-06 · $6
  • Consulting for Yescarta · 2023-03-31 · $4,250
  • Meals for Yescarta · 2023-03-24 · $50
  • Meals for Yescarta · 2023-03-24 · $50
  • Meals for Yescarta · 2023-03-24 · $50
  • Travel for Yescarta · 2023-03-23 · $265
  • Travel for Yescarta · 2023-03-23 · $1,163
Gilead SciencesYescarta$4,110
1 payment
  • Consulting for Yescarta · 2023-11-22 · $4,110
E.R. Squibb & Sons L.L.C.None$1,384
1 payment
  • Consulting · 2023-03-20 · $1,384
Pharmacyclics LLC An AbbVieEpkinly$123
4 payments
  • Meals for Epkinly · 2023-09-12 · $33
  • Meals for Epkinly · 2023-06-01 · $34
  • Meals for Imbruvica · 2023-05-05 · $22
  • Meals for Imbruvica · 2023-02-01 · $34
Adaptive BiotechnologiesClonoseq$85
1 payment
  • Meals for Clonoseq · 2023-09-12 · $85

2022: $4,834

Payments by company in 2022
IncyteMonjuvi$4,420
2 payments
  • Consulting for Monjuvi · 2022-02-15 · $2,070
  • Consulting for Monjuvi · 2022-02-01 · $2,350
Kite PharmaYescarta$172
3 payments
  • Meals for Yescarta · 2022-12-11 · $23
  • Meals · 2022-11-15 · $24
  • Meals · 2022-07-27 · $125
Adaptive BiotechnologiesNone$136
1 payment
  • Meals · 2022-06-14 · $136
Novartis PharmaceuticalsKymriah$73
1 payment
  • Meals for Kymriah · 2022-12-09 · $73
Pharmacyclics LLC an AbbVieImbruvica$33
1 payment
  • Meals for Imbruvica · 2022-11-29 · $33

2021: $1,900

Payments by company in 2021
IncyteNone$1,900
2 payments
  • Consulting · 2021-08-09 · $1,845
  • Meals · 2021-08-09 · $55

2020: $1,580

Payments by company in 2020
Kite PharmaYescarta$1,580
1 payment
  • Consulting for Yescarta · 2020-10-23 · $1,580

2019: $289

Payments by company in 2019
AmgenKyprolis$265
2 payments
  • Meals for Kyprolis · 2019-12-07 · $122
  • Meals for Kyprolis · 2019-12-07 · $143
Seattle GeneticsAdcetris$25
2 payments
  • Education for Adcetris · 2019-01-09 · $12
  • Education for Adcetris · 2019-01-09 · $12

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Kite Pharma, Inc. · Collaborative (Dahiya): Phase Ib, Investigator-Initiated, Open Label Study To Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/Or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel · 2025Their institution$876,146
Celgene Corporation · A Phase 2, Open-Label, Single Arm, Multicohort, Multicenter Trial To Evaluate the Efficacy and Safety of Jcar017 in Adult Subjects With Relapsed Or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (Nhl) · 2022Their institution$670,169
Novartis Pharmaceuticals Corporation · Phase I, Open Label, Multicenter, Dose Escalation Study of Ytb323 in Adult Patients With Cll/Sll and Dlbcl · 2025Their institution$371,906
Celgene Corporation · A Phase 2, Open-Label, Single Arm, Multicenter Tri · 2021Their institution$315,427
Kite Pharma, Inc. · A Phase 1b, Investigator- Initiated, Open Label Study To Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/Or Refractory Second Line High -Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel · 2024Their institution$239,310
Kite Pharma, Inc. · A Phase Ib, Investigator-Initiated, Open Label Study To Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/Or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel · 2023Their institution$132,000
Kite Pharma, Inc. · Isr-Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia · 2023Their institution$74,000
Kite Pharma, Inc. · A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-Cell Malignancies (Zuma-25) - Substudy C - Relapsed/Refractory Burkitt Lymphoma · 2025Their institution$70,917
Kite Pharma, Inc. · A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-Cell Malignancies (Zuma-25) - Substudy C - Relapsed/Refractory Burkitt Lymphoma · 2024Their institution$69,632
Celgene Corporation · Transcend Fl (Indolent Lymphoma) 4l+ Fl, 3l Fl, 2l Fl, 3l+ Mzl (Fol-001) - A Phase 2, Open-Label, Single Arm, Multicohort, Multicenter Trial To Evaluate the Efficacy and Safety of Jcar017 (Lisocabtagene Maraleucel) in Adult Subjects With Relapsed Or Refra · 2023Their institution$58,476
Kite Pharma, Inc. · A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-Cell Malignancies (Zuma-25) - Substudy B - Relapsed/Refractory Richter Transformation · 2023Their institution$43,220
Kite Pharma, Inc. · A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-Cell Malignancies (Zuma-25) - Substudy A - Relapsed/Refractory Waldenstrom Macroglobulinemia · 2023Their institution$43,220
Kite Pharma, Inc. · A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults With Rare B-Cell Malignancies (Zuma-25) - Substudy D - Relapsed/Refractory Hairy Cell Leukemia · 2023Their institution$43,220
Celgene Corporation · (Jcar017-Eap-001) Expanded Access (Out of Spec) - Expanded Access Protocol (Eap) of Subjects Receiving Nonconforming Lisocabtagene Maraleucel That Is Out of Specification (Oos) for Commercial Release · 2023Their institution$31,182
E.R. Squibb & Sons, L.L.C. · A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of Nktr-255 Vs Placebo Following Cd19-Directed Car-T Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma · 2024Their institution$10,040
Celgene Corporation · (Jcar017-Eap-001) Expanded Access (Out of Spec) (Bms Study Number: Ca082-P27) - Expanded Access Protocol (Eap) of Subjects Receiving Nonconforming Lisocabtagene Maraleucel That Is Out of Specification (Oos) for Commercial Release · 2022Their institution$7,932
JAZZ PHARMACEUTICALS INC. · Outcomes for Hepatic Sinusodial Obstruction Syndrome in Patients Undergoing Stem Cell Transplant: A Nationa-Wide Analysis · 2020Their institution$5,624
Kite Pharma, Inc. · A Phase 1b, Investigator-Initiated, Open Label Study To Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/Or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel · 2025Their institution$5,009
Celgene Corporation · Expanded Access Protocol (Eap) of Subjects Receiving Nonconforming Lisocabtagene Maraleucel That Is Out of Specification (Oos) for Commercial Release · 2025Their institution$2,240
Celgene Corporation · A Study To Evaluate the Efficacy and Safety of Jcar017 in Adult Subjects With Relapsed Or Refractory Indolent B-Cell Non-Hodgkin Lymphoma (Nhl) (Transcend Fl) · 2020Their institution$2,113
Novartis Pharmaceuticals Corporation · Phase I, Open Label, Multicenter, Dose Escalation Study of Ytb323 in Adult Patients With Cll/Sll and Dlbcl · 2024Their institution$333

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
76.5 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1184943730
Licence
CA A140273, OH 57.016554California A140273: Current · expires 2027-06-30
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X)
Mailing address
300 Pasteur Dr, Stanford, CA, 94305
NPI first listed
2010-05-21
NPI last updated
2022-07-01
NPI record certified
2022-07-01

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 465 Gypsy Ln Apt 404, Youngstown, OH, 44504